Last reviewed · How we verify
immune-checkpoint inhibitors therapies — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
immune-checkpoint inhibitors therapies (immune-checkpoint inhibitors therapies) — Institut Paoli-Calmettes.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| immune-checkpoint inhibitors therapies TARGET | immune-checkpoint inhibitors therapies | Institut Paoli-Calmettes | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- immune-checkpoint inhibitors therapies CI watch — RSS
- immune-checkpoint inhibitors therapies CI watch — Atom
- immune-checkpoint inhibitors therapies CI watch — JSON
- immune-checkpoint inhibitors therapies alone — RSS
Cite this brief
Drug Landscape (2026). immune-checkpoint inhibitors therapies — Competitive Intelligence Brief. https://druglandscape.com/ci/immune-checkpoint-inhibitors-therapies. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab